Metformin 1 A Pharma

Metformin, the active ingredient in Metformin 1 A Pharma, is a Biguanide presented as an oral dosage form for oral use. It reduces hepatic glucose production and improves peripheral insulin sensitivity, treating type 2 diabetes mellitus in adults.

GNH USA supplies Metformin 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin is indicated for conditions affecting glucose metabolism and insulin sensitivity.

- Type 2 diabetes mellitus: improves glycaemic control and reduces HbA1c levels. - Prediabetes (impaired fasting glucose): delays progression to overt diabetes. - Polycystic ovary syndrome (adjunct therapy): helps restore ovulatory cycles by improving insulin resistance.

Metformin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: frequent loose stools, especially at treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Vitamin B12 deficiency: may develop with long‑term therapy.

Metformin should be used with careful clinical monitoring.

- Renal function assessment: avoid or adjust dose in impaired renal clearance. - Hepatic function monitoring: contraindicated in severe liver disease. - Vitamin B12 level evaluation: consider periodic testing during prolonged use. - Acute heart failure caution: risk of lactic acidosis may increase. - Elderly patient monitoring: start at low dose and titrate slowly. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast media: can precipitate acute renal failure and lactic acidosis. - Cimetidine: may increase metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Thiazide diuretics: can increase risk of hyperglycaemia. - ACE inhibitors: may affect renal function, requiring dose adjustment. - NSAIDs: may reduce renal clearance of metformin. - Warfarin: may require INR monitoring due to potential interaction.